Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

X4 Pharmaceuticals (XFOR) Equity Ratio (2018 - 2025)

Historic Equity Ratio for X4 Pharmaceuticals (XFOR) over the last 8 years, with Q3 2025 value amounting to 0.38.

  • X4 Pharmaceuticals' Equity Ratio rose 1258.33% to 0.38 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.38, marking a year-over-year increase of 1258.33%. This contributed to the annual value of 0.15 for FY2024, which is 5641.47% down from last year.
  • Per X4 Pharmaceuticals' latest filing, its Equity Ratio stood at 0.38 for Q3 2025, which was up 1258.33% from 0.04 recorded in Q2 2025.
  • Over the past 5 years, X4 Pharmaceuticals' Equity Ratio peaked at 0.65 during Q1 2021, and registered a low of 0.01 during Q1 2024.
  • Moreover, its 5-year median value for Equity Ratio was 0.39 (2023), whereas its average is 0.39.
  • Its Equity Ratio has fluctuated over the past 5 years, first plummeted by 9777.68% in 2024, then skyrocketed by 181093.44% in 2025.
  • X4 Pharmaceuticals' Equity Ratio (Quarter) stood at 0.55 in 2021, then decreased by 13.42% to 0.48 in 2022, then dropped by 27.09% to 0.35 in 2023, then crashed by 56.41% to 0.15 in 2024, then skyrocketed by 149.1% to 0.38 in 2025.
  • Its Equity Ratio was 0.38 in Q3 2025, compared to 0.04 in Q2 2025 and 0.18 in Q1 2025.